Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.53 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.51 |
| ▸ | HPGD | P15428 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 3/20 | 0.46 |
| ▸ | APP | P05067 | 2/20 | 0.46 |
| ▸ | SNCA | P37840 | 2/20 | 0.46 |
| ▸ | RAF1 | P04049 | 2/20 | 0.45 |
| ▸ | NTRK1 | P04629 | 2/20 | 0.45 |
| ▸ | STK10 | O94804 | 3/20 | 0.44 |
| ▸ | SLK | Q9H2G2 | 3/20 | 0.44 |
| ▸ | FLT3 | P36888 | 1/20 | 0.43 |
| ▸ | CTRC | Q99895 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | PRKCB | P05771 | 2/20 | 0.41 |
| ▸ | GSK3B | P49841 | 2/20 | 0.41 |
| ▸ | PRKCG | P05129 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5873929 | 1.00 | ALDH1A1 (0.53) | ALDH1A1NPSR1HPGDMAPTAPP | |
| SCHEMBL5873835 | 0.82 | NTRK1 (0.57) | ALDH1A1NPSR1HPGDMAPTRAF1 | |
| SCHEMBL5873834 | 0.82 | NTRK1 (0.57) | ALDH1A1NPSR1HPGDMAPTRAF1 | |
| SCHEMBL5873932 | 0.81 | ALDH1A1 (0.51) | ALDH1A1NPSR1HPGDMAPTSTK10 | |
| SCHEMBL5873930 | 0.81 | ALDH1A1 (0.51) | ALDH1A1NPSR1HPGDMAPTSTK10 | |
| SCHEMBL5873901 | 0.81 | MAP3K11 (0.49) | ALDH1A1NPSR1HPGDMAPTRAF1 | |
| SCHEMBL5873896 | 0.81 | MAP3K11 (0.49) | ALDH1A1NPSR1HPGDMAPTRAF1 | |
| SCHEMBL5873908 | 0.81 | ALDH1A1 (0.53) | ALDH1A1NPSR1HPGDMAPTNTRK1 | |
| SCHEMBL5873909 | 0.81 | ALDH1A1 (0.53) | ALDH1A1NPSR1HPGDMAPTNTRK1 | |
| SCHEMBL8322866 | 0.79 | NPC1 (0.66) | ALDH1A1HPGDMAPTAPPSNCA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6818632-B2 | 3-(anilinomethylene)oxindoles | SMITHKLINE BEECHAM CORPORATION | 2004-11-16 | — | — | US | claimed |
| US-20020099071-A1 | Protein tyrosine kinase and protein serin/threonine kinase inhibitory activity; anticancer agents; treating chemotherapy induced alopecia | GLENNON KIMBERLEY CAROLINE (US) | 2002-07-25 | — | — | US | claimed |
| US-7129253-B2 | Compounds | SMITHKLINE BEECHAM CORPORATION (US) | 2006-10-31 | — | — | US | disclosed |
| US-6818632-B2 | 3-(anilinomethylene)oxindoles | SMITHKLINE BEECHAM CORPORATION | 2004-11-16 | — | — | US | disclosed |
| US-20040191210-A1 | Compounds | GLENNON KIMBERLEY CAROLINE (US) | 2004-09-30 | — | — | US | disclosed |
| US-6498176-B1 | INHIBITING TUMOR GROWTH VIA INHIBITION OF TUMOR-RELATED ANGIOGENESIS | SMITHKLINEBEECHAM CORPORATION | 2002-12-24 | — | — | US | disclosed |
| US-20020099071-A1 | Protein tyrosine kinase and protein serin/threonine kinase inhibitory activity; anticancer agents; treating chemotherapy induced alopecia | GLENNON KIMBERLEY CAROLINE (US) | 2002-07-25 | — | — | US | disclosed |
| US-6350747-B1 | PROTEIN SERINE/THREONINE KINASE AND PROTEIN TYROSINE KINASE ENZYME INHIBITORS; ANGIOGENESIS INHIBITORS; ANTITUMOR AND ANTIPROLIFERATIVE AGENTS | GLAXO WELLCOME INC. | 2002-02-26 | — | — | US | disclosed |
| EP-1165514-A1 | 3-(ANILINOMETHYLENE) OXINDOLES AS PROTEIN TYROSINE KINASE AND PROTEIN SERINE/THREONINE KINASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 2002-01-02 | — | — | EP | disclosed |
| WO-2000056710-A1 | 3-(ANILINOMETHYLENE) OXINDOLES AS PROTEIN TYROSINE KINASE AND PROTEIN SERINE/THREONINE KINASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 2000-09-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040191210-A1 | Compounds | CDK1, AKT1, RPS6KA1 | ALDH1A1 3649/4885NPSR1 1039/4885HPGD 4660/4885 |
| US-20020099071-A1 | Protein tyrosine kinase and protein serin/threonine kinase inhibitory activity; anticancer agents; treating chemotherapy induced alopecia | PRKDC, PRKX, BMX | ALDH1A1 4171/4885NPSR1 2240/4885HPGD 4191/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.